-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial re ...

Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly in oral compounds that address nuclear export dysregulation, a key mechanism in oncogenesis [3]. - The company's lead compound, XPOVIO® (selinexor), is a first-in-class oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in 50 ex-U.S. territories, including the EU, UK (as NEXPOVIO®), and China [3]. Upcoming Event - Karyopharm's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on December 10, 2025, at 12:00 p.m. ET [1]. - The event will be accessible via a live webcast on the company's investor website and will be available for replay afterward [2]. Pipeline and Focus Areas - Karyopharm has a focused pipeline targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3].

Core Insights - Karyopharm Therapeutics Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 10:30 a.m. ET in New York, NY [1] - A live webcast of the event will be available on the company's investor website and can be replayed after the event [2] Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing novel cancer therapies, particularly oral compounds that target nuclear export dysregulation, a key mechanism in cancer development [3] - The company's lead product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in 50 territories, including the EU, UK (as NEXPOVIO), and China [3] - Karyopharm's pipeline targets multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]